The U.S. Food and Drug Administration approved Johnson & Johnson’s drug Darzalex Faspro as the first treatment for adults with high-risk smoldering multiple myeloma, a precursor to the blood cancer.
Harbour BioMed, a global biopharmaceutical company, and Evinova, a global health-tech company, have entered a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback